Analysis of the utilisation of idelalisib for refractory follicular B-cell non-Hodgkin's lymphoma, October 2024
Page last updated: 14 March 2025
Drug utilisation sub-committee (DUSC)
October 2024
Abstract
Purpose
To review the utilisation of idelalisib for refractory follicular B-cell non-Hodgkin's lymphoma following amendments to the Pharmaceutical Benefits Scheme (PBS) Authority Required listing in January 2022.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Idelalisib was listed on the PBS for refractory follicular B-cell non-Hodgkin's lymphoma
on
1 September 2017.
Data Source / methodology
Authorities data and prescriptions data was extracted from the prescription database and
Authorities database maintained by the Department of Health and Aged Care, processed by
Services Australia from between 1 September 2017 and 30 June 2024. Data were extracted based on the date of supply.
Key Findings
- There were only a small number of patients being dispensed idelalisib for refractory follicular B-cell non-Hodgkin's lymphoma.
- The proportion of idelalisib for refractory follicular B-cell non-Hodgkin's lymphoma being prescribed by haematologists decreased since 1 January 2022 while the proportion being prescribed by pathologists increased.
- Fewer patients moved from the 150 mg dose to the 100 mg dose from 1 January 2022. And fewer patients commenced on the 150 mg dose and more on the 100 mg dose before transitioning to the 150 mg dose.
- Based on adverse event notifications from the Therapeutic Goods Administration (TGA), the most common adverse events associated with idelalisib treatment were infections and infestations, and gastrointestinal disorders.
